Global Stem Cell Therapy Market Report and Forecast 2024-2032

Global Stem Cell Therapy Market Outlook

The global stem cell therapy market size was valued at USD 291.51 million in 2023, driven by the increasing demand for regenerative therapies structure across the globe. The market size is anticipated to grow at a CAGR of 18.5% during the forecast period of 2024-2032 to achieve a value of USD 1,343.13 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

Stem cell therapy is a specialised form of regenerative medicine that aims to repaid damaged cells by modulating the immune system and reducing inflammation. The capabilities of stem cell therapy offers immense potential for treatment of various medical conditions ranging from autoimmune and trauma injuries to inflammatory, orthopaedic, and neurological conditions. Instead of directly targeting the conditions, stem cell therapy aims at helping the body of the patient heal itself against the condition. Stem cell therapy utilises stem cells, the cells from which other cells are generated for specific functions, or derivatives of stem cells to trigger the body‘s healing.  

• The increasing prevalence of chronic conditions such as cancer, musculoskeletal and cardiovascular diseases, and leukaemia, among others, is driving the stem cell therapy market growth. In addition, the market growth is getting fuelled by the rising health awareness, rising disposable income, and sedentary lifestyles led by the working population.

• The increasing geriatric population, along with the surge in oncological, neurological, and orthopaedic conditions cases associated with them is anticipated to provide impetus to the stem cell therapy market in the forecast period. The market is anticipated to be aided by the increasing prevalence of wounds and injuries, infused by the growing inclination of youth towards sports and adventure.

• The rising healthcare expenditure and technological advancements in the healthcare infrastructure across the emerging economies are improving the diagnosis and treatment standards across the healthcare units which are further boosting the market growth.

• The growing research and development activities, favoured by fundings and initiatives by various governments, aimed towards innovating in the field of stem cell research are the crucial stem cell therapy market trends.

Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on treatment type, the market is segmented into allogeneic stem cell therapy, autologous stem cell therapy, syngeneic stem cell therapy. On the basis of product type, the stem cell therapy market is classified into adult stem cell, human embryonic cell, and pluripotent stem cell, among others. By application, the market is categorised into musculoskeletal disorders, neurological disorders, oncology disorders, cardiovascular disorders, cancer, and wounds and injuries, among others. The regional markets for stem cell therapy are divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global stem cell therapy market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.

• Thermo Fisher Scientific

• Bayer AG

• Takeda Pharmaceutical Company Limited

• MEDIPOST Co., Ltd.

• JCR Pharmaceuticals Co., Ltd.

• Astellas Pharma Inc.

• Mesoblast Ltd.

• Novadip Biosciences S.A.

• Nuvasive Inc

• Amgen Inc

• Others

Market Share by Treatment Type

The allogeneic stem cell therapy segment is expected to witness a healthy growth in the forecast period, increasing its stem cell therapy market share. In this treatment procedure, stem cells are matched from a donor and transplanted into the patient whose immune system gets a boost after other types of treatment are administered. While the transplanted stem cells do help in improving the immune system of the patient and in fighting against conditions such as cancers, there is a risk of rejection with the stem cells getting targeted and destroyed by the patient’s immune system.   

Syngeneic stem cell therapy, based on treatment type, has a high success rate, however, is restricted in applications as stem cells are sourced from identical twins of the patient. This type of stem cell therapy is uses to treat various types of conditions such as Hodgkin lymphoma, leukaemia, multiple myeloma, Myelodysplastic syndrome, Non-Hodgkin lymphoma, severe aplastic anaemia, and testicular cancer, among others. Moreover, in this therapy, as stem cells are donated by healthy identical twins, reducing risks of rejection or host versus graft disease, increasing the success rate of the procedure significantly. 

Market Share by Product Type

Based on product type, the human embryonic cell segment accounts for a significant share in the stem cell therapy market. This can be attributed to the versatility of this type of cell which makes it effective in the treatment and repair of diseased organs or tissues. In addition, human embryonic cell accelerate the therapy process by dividing into more stem cells than any other product type. With the increase in in-vitro fertilisation clinics and operations, extracting human embryonic cells has become easier.

On the other hand, the adult stem cell segment is expected to witness a heightened growth in the forecast period. Adult stem cells are present in the most critical areas of the body such as intestine, muscle, brain, and heart. Hence, these types of cells can facilitate the regeneration of cells which can treat chronic heart or muscle-related conditions. The targeted applications of these cells and easy availability amongst a growing population is further expected to influence the stem cell therapy market price. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Thermo Fisher Scientific is a key supplier of scientific instruments, reagents, and consumables. The company caters to the demands of medical science by providing custom-tailored solutions, biotech products, medical devices, pharmaceuticals, drug innovations, and medicines, among others. Thermo Fisher Scientific was founded in 1956 and is headquartered in Massachusetts, United States. 

Bayer AG is a leading pharmaceutical company which develops, discovers, innovates, manufactures, and markets products which cater to the demands of human health treatment and agriculture. The company offers products which are applied in the treatment of cardiovascular diseases, women’s health, cancer, and ophthalmological diseases, among others. Bayer AG was established in 1863 in Barmen, Germany.

Takeda Pharmaceutical Company Limited is a global research-based company which focuses on developing high-end pharmaceuticals. This company facilitates research and development activities and clinical trials, with a focus on oncological, neuroscience, gastroenterology, and plasma-derived therapies, among others. It was founded in 1781 and is headquartered in Osaka, Japan. 

Other market players include MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Astellas Pharma Inc., Mesoblast Ltd., Novadip Biosciences S.A., Nuvasive Inc, and Amgen Inc, among others.

Key Highlights of the Report